CO2020008308A2 - Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico - Google Patents

Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Info

Publication number
CO2020008308A2
CO2020008308A2 CONC2020/0008308A CO2020008308A CO2020008308A2 CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2 CO 2020008308 A CO2020008308 A CO 2020008308A CO 2020008308 A2 CO2020008308 A2 CO 2020008308A2
Authority
CO
Colombia
Prior art keywords
relaxin
therapeutic use
chain peptides
lipidated
modified
Prior art date
Application number
CONC2020/0008308A
Other languages
English (en)
Inventor
Olivier Duclos
Stéphane Illiano
Sergio Mallart
Claire Minoletti-Hochepied
Elisabetta Bianchi
Raffaele Ingenito
Paola Magotti
Alessia Santoprete
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2020008308A2 publication Critical patent/CO2020008308A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un péptido de Relaxina monocatenario biológicamente activo que tiene la siguiente fórmula (I): Nter-Ac-X10-E-G-R-E-X15-V-R-X18-X19-I-X21-X22-E-G-X25-S-X27-X28-X29-X30-X31-X32-X33-NH2-Cter o una sal o solvato de este. También trata sobre una composición farmacéutica que comprende al menos un péptido de la invención, y el péptido o la composición farmacéutica para su uso como medicamento.
CONC2020/0008308A 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico CO2020008308A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305094 2018-01-31
PCT/EP2019/052298 WO2019149782A1 (en) 2018-01-31 2019-01-30 Modified lipidated relaxin b chain peptides and their therapeutic use

Publications (1)

Publication Number Publication Date
CO2020008308A2 true CO2020008308A2 (es) 2020-10-30

Family

ID=61223862

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0008308A CO2020008308A2 (es) 2018-01-31 2020-07-06 Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico

Country Status (29)

Country Link
US (3) US10961295B2 (es)
EP (1) EP3746467B1 (es)
JP (1) JP7295871B2 (es)
KR (1) KR102755938B1 (es)
CN (1) CN111770934B (es)
AR (1) AR114325A1 (es)
AU (1) AU2019214358B2 (es)
BR (1) BR112020014834A2 (es)
CA (1) CA3089657A1 (es)
CO (1) CO2020008308A2 (es)
DK (1) DK3746467T3 (es)
ES (1) ES3058633T3 (es)
FI (1) FI3746467T3 (es)
HR (1) HRP20260016T1 (es)
IL (2) IL276170B2 (es)
LT (1) LT3746467T (es)
MA (1) MA52994A (es)
MX (1) MX2020008096A (es)
MY (1) MY199821A (es)
NZ (1) NZ766762A (es)
PH (1) PH12020551118A1 (es)
PL (1) PL3746467T3 (es)
PT (1) PT3746467T (es)
RS (1) RS67606B1 (es)
SG (1) SG11202006903WA (es)
SI (1) SI3746467T1 (es)
TW (1) TWI763972B (es)
UY (1) UY38069A (es)
WO (1) WO2019149782A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
WO2023086913A2 (en) 2021-11-11 2023-05-19 Tectonic Therapeutic, Inc. Relaxin-2 fusion protein analogs and methods of using same
CN115998842B (zh) * 2022-09-02 2025-08-26 郑州大学第一附属医院 一种逆转肝星形细胞激活的仿生纳米药物及其应用
EP4713001A2 (en) 2023-05-18 2026-03-25 Tectonic Operating Company, Inc. Relaxin-2 fusion protein analogs and methods of using same
KR20250054870A (ko) * 2023-10-16 2025-04-24 (주)케어젠 피부 상태 개선 활성을 갖는 펩타이드 및 이의 용도

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110288011A1 (en) * 2008-12-05 2011-11-24 Jean-Paul Castaigne Peptide therapeutic conjugates and uses thereof
EP2460527A1 (en) * 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
EP2524915A1 (en) * 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
AU2012280474A1 (en) * 2011-07-01 2014-01-16 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
TW201315739A (zh) * 2011-07-01 2013-04-16 拜耳智慧財產有限公司 鬆弛素（ｒｅｌａｘｉｎ）融合多肽類及其用途
AU2012291972B2 (en) * 2011-08-04 2017-03-09 Pharis Biotec Gmbh Process for preparing human relaxin-2
WO2013177529A1 (en) * 2012-05-24 2013-11-28 Angion Biomedica Corp. Relaxin-like compounds and uses thereof
WO2015038938A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
CA2945838C (en) * 2014-04-17 2022-08-16 The Florey Institute Of Neuroscience And Mental Health Modified relaxin b chain peptides
HUE052977T2 (hu) * 2014-04-22 2021-06-28 Txp Pharma Gmbh Elágazó szénláncú aminosav-próbával rendelkezõ peptid analóg(ok)
SG10201912034UA (en) * 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
TW201934572A (zh) * 2018-01-31 2019-09-01 法商賽諾菲公司 經修飾之鬆弛素ｂ鏈胜肽及其治療用途
MY199821A (en) 2018-01-31 2023-11-23 Sanofi Sa Modified lipidated relaxin b chain peptides and their therapeutic use
WO2019149781A1 (en) * 2018-01-31 2019-08-08 Sanofi Modified lipidated relaxin b chain peptides and their therapeutic use
TWI844709B (zh) * 2019-07-31 2024-06-11 美商美國禮來大藥廠 鬆弛素(relaxin)類似物及其使用方法
WO2023028008A2 (en) * 2021-08-23 2023-03-02 River 2 Renal Corp. Combination of relaxin and vasopressin analogues for treatment of renal disorders or conditions

Also Published As

Publication number Publication date
PL3746467T3 (pl) 2026-04-13
PT3746467T (pt) 2026-01-13
US20240218042A1 (en) 2024-07-04
CN111770934B (zh) 2024-10-18
US10961295B2 (en) 2021-03-30
AR114325A1 (es) 2020-08-19
AU2019214358A1 (en) 2020-08-20
CA3089657A1 (en) 2019-08-08
JP2021512099A (ja) 2021-05-13
US20190233494A1 (en) 2019-08-01
SI3746467T1 (sl) 2026-02-27
DK3746467T3 (da) 2026-01-12
RU2020126210A (ru) 2022-02-28
CN111770934A (zh) 2020-10-13
IL276170B2 (en) 2025-03-01
US11725036B2 (en) 2023-08-15
SG11202006903WA (en) 2020-08-28
IL276170B1 (en) 2024-11-01
UY38069A (es) 2019-08-30
TWI763972B (zh) 2022-05-11
KR102755938B1 (ko) 2025-01-20
NZ766762A (en) 2026-03-27
FI3746467T3 (fi) 2026-01-16
MA52994A (fr) 2021-05-05
US20210292387A1 (en) 2021-09-23
MX2020008096A (es) 2020-09-24
TW201940505A (zh) 2019-10-16
EP3746467B1 (en) 2025-10-08
HRP20260016T1 (hr) 2026-02-27
RS67606B1 (sr) 2026-01-30
BR112020014834A2 (pt) 2020-12-08
MY199821A (en) 2023-11-23
KR20200116085A (ko) 2020-10-08
AU2019214358B2 (en) 2023-05-25
LT3746467T (lt) 2026-01-26
IL316406A (en) 2024-12-01
IL276170A (en) 2020-09-30
ES3058633T3 (en) 2026-03-12
WO2019149782A1 (en) 2019-08-08
EP3746467A1 (en) 2020-12-09
PH12020551118A1 (en) 2021-07-05
JP7295871B2 (ja) 2023-06-21

Similar Documents

Publication Publication Date Title
UY38069A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114324A1 (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
ES2619322T3 (es) Agente inductor de inmunidad
CL2019003091A1 (es) Terapia de combinación.
PE20241305A1 (es) Analogos de amilina
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
SA521421715B1 (ar) تركيبات سيماجلوتيد ثابتة واستخداماتها
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
PE20160244A1 (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos
BR112018003898A2 (pt) material auxiliar para aplicação no tecido de cólon
MX2015015500A (es) Composiciones de cenicriviroc y metodos para elaborarlas y usarlas.
MX392572B (es) Compuestos del péptido yy (pyy) selectivos y sus usos.
AR094178A1 (es) Derivados de exendina-4 funcionalizada
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
UY37705A (es) Nuevos derivados de pirazol bicíclicos
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
UY35703A (es) Anticuerpos contra el inhibidor-1 del activador de plasminógeno (pai-1) y usos de los mismos
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
CL2019003441A1 (es) Puestos de mic-1 y usos de estos.
MX2017013636A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas.
AR097613A1 (es) Dosificación de péptidos co-antagonistas gip/glp-1 para administración a humanos
RU2014130894A (ru) Пептид, обладающий нейропротекторной и ноотропной активностью, и фармацевтическая композиция на его основе
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2017013643A (es) Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y una matriz.